Eeckhout Célien, Bouckaert Eline, Verleyen Dagmar, De Bruyckere Thomas, Cosyn Jan
Faculty of Medicine and Health Sciences, Oral Health Sciences, Department of Periodontology and Oral Implantology, Ghent University, Corneel Heymanslaan 10, B-9000 Ghent, Belgium.
Faculty of Medicine and Pharmacy, Oral Health Research Group (ORHE), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, B-1090 Brussels, Belgium.
J Clin Med. 2020 May 22;9(5):1568. doi: 10.3390/jcm9051568.
Xenogeneic soft tissue substitutes are currently being investigated as an alternative to subepithelial connective tissue grafts (CTG) with the intention to avoid postoperative morbidity associated with autologous grafting. The aim of the present study was to volumetrically evaluate the effectiveness and mid-long-term stability of a porcine-derived collagen matrix (PDCM) (Mucoderm, Botiss gmbh, Berlin, Germany) in increasing soft tissue volume at the buccal aspect of molar implant sites.
Periodontally healthy non-smoking patients with a single tooth gap in the molar area were selected for a prospective case series. All sites had a bucco-oral bone dimension of at least 8 mm and demonstrated a horizontal alveolar defect. A wide diameter implant was placed under the elevated buccal flap and a PDCM was applied. The primary outcome was the linear increase in buccal soft tissue profile (BSP) within a well-defined area of interest. This was performed with designated software (SMOP; Swissmeda AG, Zurich, Switzerland) on the basis of superimposed digitalized study casts taken before surgery (T0), immediately after surgery (T1), at three months (T2), one year (T3) and three years (T4). Secondary outcomes were alveolar process deficiency and clinical parameters.
Fourteen out of 15 treated patients attended the three-year re-assessment (four females; mean age 51.4 years). Mean linear increase in BSP at T1 was 1.53 mm ( = 0.001). The PDCM showed substantial resorption at T2 (1.02 mm or 66.7%) ( = 0.001). Thereafter, a 0.66 mm volume gain was observed ( = 0.030), possibly due to the installation of a permanent crown displacing the soft tissues to the buccal aspect. This resulted in a linear increase in BSP of 1.17 mm (76.5%) at T4. Alveolar process deficiency significantly reduced over time ( = 0.004). However, 50% of patients still demonstrated a slight (6/14) or obvious (1/14) alveolar process deficiency at study termination. Implants demonstrated healthy clinical conditions.
The PDCM demonstrated marked resorption during the early stages of healing. Due to the matrix thickening the tissues, and the permanent crown displacing the tissues, 76.5% of the initial increase in BSP could be maintained over a three-year period. Half of the patients failed to show perfect soft tissue convexity at the buccal aspect.
目前正在研究异种软组织替代物,作为上皮下结缔组织移植(CTG)的替代方法,目的是避免与自体移植相关的术后发病率。本研究的目的是通过体积评估猪源胶原基质(PDCM)(Mucoderm,Botiss gmbh,柏林,德国)在增加磨牙种植部位颊侧软组织体积方面的有效性和中长期稳定性。
选择磨牙区有单个牙间隙的牙周健康非吸烟患者进行前瞻性病例系列研究。所有部位的颊侧骨宽度至少为8mm,且存在水平牙槽骨缺损。在翻起的颊侧瓣下植入宽直径种植体,并应用PDCM。主要结局是在明确界定的感兴趣区域内颊侧软组织轮廓(BSP)的线性增加。这是使用指定软件(SMOP;Swissmeda AG,苏黎世,瑞士),根据术前(T0)、术后即刻(T1)、术后三个月(T2)、一年(T3)和三年(T4)拍摄的数字化研究模型叠加进行的。次要结局是牙槽突缺损和临床参数。
15例接受治疗的患者中有14例参加了三年的重新评估(4名女性;平均年龄51.4岁)。T1时BSP的平均线性增加为1.53mm(P = 0.001)。PDCM在T2时显示出大量吸收(1.02mm或66.7%)(P = 0.001)。此后,观察到体积增加了0.66mm(P = 0.030),这可能是由于永久冠的安装将软组织推移到颊侧所致。这导致T4时BSP线性增加1.17mm(76.5%)。牙槽突缺损随时间显著减少(P = 0.004)。然而,在研究结束时,50%的患者仍表现出轻微(6/14)或明显(1/14)的牙槽突缺损。种植体显示出健康的临床状况。
PDCM在愈合早期表现出明显吸收。由于基质使组织增厚,以及永久冠使组织移位,BSP最初增加量的76.5%在三年期间得以维持。一半的患者在颊侧未表现出完美的软组织凸度。